Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment.

Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment.
复制标题

肺癌中的肿瘤坏死因子:生物学中的复杂作用和对治疗的抵抗。

DOI:
10.1016/j.neo.2020.12.006
复制
发表时间:
2021-03
期刊:
Neoplasia (New York, N.Y.)
影响因子:
--
通讯作者:
Habib AA
Habib AA
中科院分区:
其他
文献类型:
--
作者:
Gong K;Guo G;Beckley N;Zhang Y;Yang X;Sharma M;Habib AA

文献摘要

参考文献

被引文献

相似文献

肿瘤坏死因子(TNF)及其受体在非小细胞肺癌(NSCLC)中广泛表达。 TNF 在炎症中具有明确的作用,并且在炎症诱发的癌症中也发挥着关键作用。 TNF 可诱导癌细胞死亡,并已被用作某些类型癌症的治疗方法。然而,TNF 可能在多种类型的癌症(包括非小细胞肺癌)中发挥致癌作用。 TNF 是转录因子 NF-κB 的关键激活剂。反过来,NF-κB 是炎症诱导的癌症中 TNF 的关键效应子。来自癌症基因组图谱数据库的数据表明,TNF 可能是 NSCLC 的生物标志物,并表明 TNF 及其受体在 NSCLC 中发挥着复杂的作用。最近的研究报道,在 NSCLC 中,由于表皮生长因子受体 (EGFR) 抑制的靶向治疗,TNF 迅速上调,并且这种上调导致 NF-κB 激活。 TNF 上调和随后的 NF-κB 激活在介导 NSCLC EGFR 抑制的原发性和继发性耐药性中发挥着关键作用,EGFR 和 TNF 的联合抑制可以克服实验模型中的治疗耐药性。 TNF 可能介导免疫治疗的毒副作用,也可能调节对免疫检查点抑制剂的抵抗力。抑制TNF的药物广泛用于治疗各种炎症和风湿性疾病,并且与NSCLC和其他癌症的靶向治疗相结合非常有用。
Tumor necrosis factor (TNF) and its receptors are widely expressed in non-small cell lung cancer (NSCLC). TNF has an established role in inflammation and also plays a key role in inflammation-induced cancer. TNF can induce cell death in cancer cells and has been used as a treatment in certain types of cancer. However, TNF is likely to play an oncogenic role in multiple types of cancer, including NSCLC. TNF is a key activator of the transcription factor NF-κB. NF-κB, in turn, is a key effector of TNF in inflammation-induced cancer. Data from The Cancer Genome Atlas database suggest that TNF could be a biomarker in NSCLC and indicate a complex role for TNF and its receptors in NSCLC. Recent studies have reported that TNF is rapidly upregulated in NSCLC in response to targeted treatment with epidermal growth factor receptor (EGFR) inhibition, and this upregulation leads to NF-κB activation. The TNF upregulation and consequent NF-κB activation play a key role in mediating both primary and secondary resistance to EGFR inhibition in NSCLC, and a combined inhibition of EGFR and TNF can overcome therapeutic resistance in experimental models. TNF may mediate the toxic side effects of immunotherapy and may also modulate resistance to immune checkpoint inhibitors. Drugs inhibiting TNF are widely used for the treatment of various inflammatory and rheumatologic diseases and could be quite useful in combination with targeted therapy of NSCLC and other cancers.
DOI: 10.1093/neuonc/noz127
发表时间: 2019-12-01
期刊: NEURO-ONCOLOGY
影响因子: 15.9
作者:
Guo, Gao;Gong, Ke;Habib, Amyn A.
通讯作者: Habib, Amyn A.
DOI: 10.1038/nn.4584
发表时间: 2017-08
影响因子: 25
作者:
Guo G;Gong K;Ali S;Ali N;Shallwani S;Hatanpaa KJ;Pan E;Mickey B;Burma S;Wang DH;Kesari S;Sarkaria JN;Zhao D;Habib AA
通讯作者: Habib AA
DOI: 10.1038/onc.2009.198
发表时间: 2009-08
期刊: ONCOGENE
影响因子: 8
作者:
Gazdar, A. F.
通讯作者: Gazdar, A. F.
DOI: 10.4049/jimmunol.165.5.2719
发表时间: 2000-09-01
影响因子: 4.4
作者:
Chen, CC;Sun, YT;Chiu, KT
通讯作者: Chiu, KT
DOI: 10.2741/2881
发表时间: 2008-01-01
影响因子: 3.1
作者:
Bertazza, Loris;Mocellin, Simone
通讯作者: Mocellin, Simone